חברות הייטק בישראל ‹ MediWound ‹ Production Operator
כישורים מהמשרה
Production OperationsSafety ProtocolsQuality StandardsTechnical EnglishAttention to DetailTeamworkClean Room ExperienceDocumentationEquipment OperationCollaborationBatch RecordsTrainingCleaning TasksProactive ApproachCommitment to Quality
תיאור המשרה
Join our pharmaceutical manufacturing team as a Production Operator! In this role, you’ll operate machinery, uphold quality standards, and help maintain a safe production environment. If you have experience in production operations and a strong commitment to safety and procedure, this is a fantastic opportunity to make an impact in a crucial position. Ready to be part of a team focused on quality and excellence? Apply now!
What will you do?
Perform production tasks following standard operating procedures (SOPs) in a pharmaceutical manufacturing setting.
Operate and monitor equipment to ensure efficient, safe, and compliant production processes.
Accurately document production activities, maintaining detailed and complete batch records.
Collaborate with cross-functional teams to achieve production targets and address process-related issues.
Adhere to all safety protocols and participate in ongoing training to ensure a safe work environment.
Maintain cleanliness and organization in the production area, including routine cleaning tasks.
What should you have?
High school diploma required; technical certifications are a plus.
Minimum of 5 years' experience in pharmaceutical, medical device, biotech (required).
Clean room experience is mandatory (grade A to D rooms).
Proficient in technical English (reading and writing) – mandatory.
Strong work ethic, responsibility, patience, attention to detail, and teamwork skills.
Full-time availability with flexibility for additional hours (no shift work).
Proactive approach and a strong commitment to quality and accuracy.
על MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.